PBA
VRDN icon

Paradigm Biocapital Advisors’s Viridian Therapeutics VRDN Stock Holding History

Paradigm Biocapital Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124M Buy
6,723,788
+3,574,895
+114% +$57.6M 2.31% 16
2026
Q1 		$61.6M Buy
3,148,893
+1,705,791
+118% +$50.7M 1.26% 22
2025
Q4 		$44.9M Sell
1,443,102
-1,166,251
-45% -$32M 1.15% 22
2025
Q3 		$56.3M Sell
2,609,353
-132,223
-5% -$2.38M 1.6% 19
2025
Q2 		$38.3M Buy
2,741,576
+646,497
+31% +$8.77M 1.64% 19
2025
Q1 		$28.2M Buy
2,095,079
+275,000
+15% +$4.68M 1.29% 20
2024
Q4 		$34.9M Sell
1,820,079
-1,075,610
-37% -$23.4M 1.21% 21
2024
Q3 		$65.9M Sell
2,895,689
-660
-0% -$10.8K 2.23% 14
2024
Q2 		$37.7M Sell
2,896,349
-2,135,071
-42% -$29.6M 1.44% 22
2024
Q1 		$88.1M Buy
5,031,420
+236,932
+5% +$4.59M 3.1% 15
2023
Q4 		$104M Buy
4,794,488
+1,112,741
+30% +$17.6M 4.89% 7
2023
Q3 		$56.5M Buy
3,681,747
+1,266,491
+52% +$24.2M 3.83% 12
2023
Q2 		$57.5M Buy
2,415,256
+329,558
+16% +$8.45M 4.44% 8
2023
Q1 		$53.1M Buy
2,085,698
+334,531
+19% +$10.7M 5.03% 8
2022
Q4 		$51.2M Buy
1,751,167
+114,956
+7% +$2.65M 6% 6
2022
Q3 		$33.6M Buy
1,636,211
+329,642
+25% +$5.93M 4.47% 9
2022
Q2 		$15.1M Buy
1,306,569
+50,518
+4% +$679K 3.01% 13
2022
Q1 		$23.2M Buy
1,256,051
+47,000
+4% +$903K 6.14% 6
2021
Q4 		$23.9M Buy
+1,209,051
New +$22.5M 6.83% 4

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Paradigm Biocapital Advisors's VRDN Position: Q2 2026 in Review

Paradigm Biocapital Advisors increased its Viridian Therapeutics (VRDN) stake by 114% in Q2 2026, buying an estimated $57.6M and bringing the position to 6,723,788 shares worth $124M. The position accounts for 2.31% of the portfolio, ranked #16.

Paradigm Biocapital Advisors first reported a position in VRDN in Q4 2021 and has held it in 19 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Paradigm Biocapital Advisors held 6,723,788 shares of Viridian Therapeutics worth $124M as of Q2 2026.
  • Paradigm Biocapital Advisors bought 3,574,895 Viridian Therapeutics shares in Q2 2026, an estimated $57.6M.
  • Viridian Therapeutics made up 2.31% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #16 holding.
  • Paradigm Biocapital Advisors first reported a position in Viridian Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.